var data={"title":"Dolasetron: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dolasetron: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6066?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dolasetron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dolasetron: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dolasetron-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dolasetron: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162413\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anzemet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162442\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiemetic;</li>\n      <li>\n        Selective 5-HT<sub>3</sub> Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162418\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Anzemet injection has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Use of intravenous dolasetron is contraindicated for the prevention of chemotherapy induced nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-associated nausea and vomiting (including initial and repeat courses):</b> Oral: 100 mg within 1 hour before chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative nausea and vomiting:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i> IV: 12.5 mg ~15 minutes before cessation of anesthesia (do not exceed the recommended dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> IV: 12.5 mg as soon as nausea or vomiting present (do not exceed the recommended dose)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162435\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dolasetron-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dolasetron: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Anzemet injection has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-associated nausea and vomiting (including initial and repeat courses): </b> Children 2 to 16 years: Oral: 1.8 mg/kg within 1 hour before chemotherapy; maximum: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative nausea and vomiting:</b> Children 2 to 16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1.2 mg/kg within 2 hours before surgery; maximum: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.35 mg/kg ~15 minutes before cessation of anesthesia; maximum: 12.5 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.35 mg/kg as soon as nausea or vomiting present; maximum: 12.5 mg/dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162419\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9662304\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; however, ECG monitoring is recommended in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9662305\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162394\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anzemet: 20 mg/mL (0.625 mL [DSC], 5 mL [DSC], 25 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anzemet: 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162379\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50640550\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Anzemet injection has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162396\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: IV injection may be given either undiluted as an IV push over 30 seconds or diluted in 50 mL of compatible fluid and infused over 15 minutes. Flush line before and after dolasetron administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: When unable to administer in tablet form, dolasetron injection may be diluted in apple or apple-grape juice and taken orally; this dilution is stable for 2 hours at room temperature (Anzemet prescribing information 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162395\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Prevention and treatment of postoperative nausea and vomiting in adults and children &ge;2 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (initial and repeat courses) in adults and children &ge;2 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162450\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anzemet may be confused with Aldomet, Antivert, Avandamet</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dolasetron may be confused with granisetron, ondansetron, palonosetron</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162386\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events may vary according to indication and route of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%: Central nervous system: Headache (oral: 18% to 23%; IV: 9%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Bradycardia (4% to 5%; may be severe after IV administration), tachycardia (&le;3%), edema (&lt;2%), facial edema (&lt;2%), flushing (&lt;2%), hypotension (&lt;2%; may be severe after IV administration), orthostatic hypotension (&lt;2%), peripheral edema (&lt;2%), peripheral ischemia (&lt;2%), phlebitis (&lt;2%), sinus arrhythmia (&lt;2%), thrombophlebitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (oral: 3% to 6%), dizziness (1% to 6%), pain (&le;3%), abnormal dreams (&lt;2%), agitation (&lt;2%), anxiety (&lt;2%), ataxia (&lt;2%), chills (&le;2%), confusion (&lt;2%), depersonalization (&lt;2%), paresthesia (&lt;2%), shivering (&le;2%), sleep disorder (&lt;2%), twitching (&lt;2%), vertigo (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis (&lt;2%), skin rash (&lt;2%), urticaria (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (oral: 2% to 5%), dyspepsia (&le;3%), abdominal pain (&lt;2%), anorexia (&lt;2%), constipation (&lt;2%), dysgeusia (&lt;2%), pancreatitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Dysuria (&lt;2%), hematuria (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic and oncologic: Anemia (&lt;2%), hematoma (&lt;2%), prolonged prothrombin time (&lt;2%), prolonged partial thromboplastin time (&lt;2%), purpura (&lt;2%), thrombocytopenia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hyperbilirubinemia (&lt;2%), increased serum alkaline phosphatase (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Anaphylaxis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Burning sensation at injection site (IV: &lt;2%), pain at injection site (IV: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), myalgia (&lt;2%), tremor (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Photophobia (&lt;2%), visual disturbance (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Acute renal failure (&lt;2%), polyuria (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchospasm (&lt;2%), dyspnea (&lt;2%), epistaxis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal T waves on ECG, appearance of U waves on ECG, atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block (left and right), cardiac arrest, chest pain, extrasystoles (APCs or VPCs), increased serum ALT (transient), increased serum AST (transient), ischemic heart disease, nodal arrhythmia, palpitations, prolongation P-R interval on ECG (dose dependent), prolonged Q-T interval on ECG, serotonin syndrome, slow R wave progression, ST segment changes on ECG, syncope (may be severe after IV administration), torsades de pointes, ventricular arrhythmia , ventricular fibrillation cardiac arrest (IV), ventricular tachycardia (IV), wide complex tachycardia (IV), widened QRS complex on ECG (dose-dependent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162399\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Hypersensitivity to dolasetron or any component of the formulation; intravenous administration is contraindicated when used for prevention of chemotherapy-associated nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Hypersensitivity to dolasetron or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162383\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: Use with caution in patients allergic to other 5-HT<sub>3</sub> receptor antagonists; cross-reactivity has been reported with other 5-HT<sub>3</sub> receptor antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; ECG effects: Dolasetron is associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT), usually occurring 1-2 hours after IV administration and lasting 6-8 hours; however, may last &ge;24 hours. May rarely lead to heart block or arrhythmia. Clinically relevant QT interval prolongation may occur resulting in torsade de pointes, when used in conjunction with other agents that prolong the QT interval (eg, Class I and III antiarrhythmics). Avoid use in patients at risk of QT prolongation and/or ventricular arrhythmia (eg, patients with congenital long QT syndrome, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], and cumulative high-dose anthracycline therapy). Correct potassium or magnesium abnormalities prior to initiating therapy. IV formulations of 5-HT<sub>3</sub> antagonists have more association with ECG interval changes, compared to oral formulations. Reduction in heart rate may also occur with the 5-HT<sub>3</sub> antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Serotonin syndrome has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonists have occurred in a post-anesthesia setting or in an infusion center. Serotonin syndrome has also been reported following overdose of another 5-HT<sub>3</sub> receptor antagonist. Monitor patients for signs of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. If serotonin syndrome occurs, discontinue 5-HT<sub>3</sub> receptor antagonist treatment and begin supportive management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: ECG monitoring is recommended in geriatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use with caution in children and adolescents who have or may develop QTc prolongation; rare cases of supraventricular and ventricular arrhythmias, cardiac arrest, and MI have been reported in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: ECG monitoring is recommended in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Chemotherapy-related emesis: <b>For chemotherapy-associated nausea and vomiting, should be used on a scheduled basis, not on an &quot;as needed&quot; (PRN) basis,</b> since data support the use of this drug only in the prevention of nausea and vomiting (due to antineoplastic therapy) and not in the rescue of nausea and vomiting. Not intended for treatment of nausea and vomiting or for chronic continuous therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postoperative nausea and vomiting: If the prophylaxis dolasetron dose has failed, a repeat dose should not be administered as rescue or treatment for postoperative nausea and vomiting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162437\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162388\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8592&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Dolasetron may enhance the arrhythmogenic effect of Mequitazine.  Management: Concurrent administration of intravenous dolasetron with mequitazine is contraindicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: Dolasetron may enhance the arrhythmogenic effect of Panobinostat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9662223\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food does not affect the bioavailability of oral doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162390\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F759349\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20306043\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dolasetron is excreted in breast milk. The manufacturer recommends that caution be exercised when administering dolasetron to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162392\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG (in patients with cardiovascular disease, elderly, renally impaired, those at risk of developing hypokalemia and/or hypomagnesemia); potassium, magnesium </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162382\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective serotonin receptor (5-HT<sub>3</sub>) antagonist, blocking serotonin both peripherally (primary site of action) and centrally at the chemoreceptor trigger zone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162398\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Hydrodolasetron: Children: 5.9 to 7.4 L/kg; Adults: 5.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Hydrodolasetron: 69% to 77% (50% bound to alpha<sub>1</sub>-acid glycoprotein)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; rapid reduction by carbonyl reductase to hydrodolasetron (active metabolite); further metabolized by CYP2D6, CYP3A, and flavin monooxygenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Not affected by food; Children: 59% (formulation not specified); Adults: ~75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dolasetron: IV: &le;10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hydrodolasetron: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Children: 5.5 hours; Adolescents: 6.4 hours; Adults: 8.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: Children: 4.8 hours; Adults: 7.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe renal impairment: 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe hepatic impairment: 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Hydrodolasetron: IV: 0.6 hours; Oral: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine ~67% (dolasetron: &lt;1% excreted unchanged in urine; hydrodolasetron: 53% to 61% of the total dose); Feces ~33%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162402\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Anzemet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (5): $432.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (5): $573.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162403\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anemet (DE);</li>\n      <li>Anzemet (AR, AT, AU, BB, BG, CH, CR, DO, GB, GR, GT, HN, IT, KR, MX, NI, NL, PA, PL, SE, SV, VE);</li>\n      <li>Li Bi Fu (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anzemet (dolasetron) injection [prescribing information]: Bridgewater, NJ: Sanofi-Aventis; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anzemet (dolasetron) tablets [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al, &quot;Antiemetics: American Society of Clinical Oncology clinical practice guideline update,&quot; <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Meyer TA, Apfel CC, et al, &ldquo;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&rdquo; <i>Anesth Analg</i>, 2007, 105(6):1615-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/18042859/pubmed\" target=\"_blank\" id=\"18042859\">18042859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovac Al, Scuderi PE, et al, &ldquo;Treatment of Postoperative Nausea and Vomiting With Single Intravenous Doses of Dolasetron Mesylate: A Multicenter Trial,&rdquo; <i>Anesth Analg</i>, 1997, 85(3):546-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/9296407/pubmed\" target=\"_blank\" id=\"9296407\">9296407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kris MG, Pendergrass KB, Navari RM, et al, &ldquo;Prevention of Acute Emesis in Cancer Patients Following High-Dose Cisplatin With the Combination of Oral Dolasetron and Dexamethasone,&rdquo; <i>J Clin Oncol</i>, 1997, 15(5):2135-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/9164228/pubmed\" target=\"_blank\" id=\"9164228\">9164228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navari RM and Koeller JM, &ldquo;Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine<sub>3</sub> Receptor Antagonists,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(9):1276-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/12921512/pubmed\" target=\"_blank\" id=\"12921512\">12921512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steiner ME, Lensmeyer G, and Vermeulen LC, &ldquo;Stability and Sterility of Dolasetron Mesylate in Syringes Stored at Room Temperature,&rdquo; <i>Am J Health Syst Pharm</i>, 2005, 62(9):896-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dolasetron-drug-information/abstract-text/15851493/pubmed\" target=\"_blank\" id=\"15851493\">15851493</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8592 Version 144.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F162413\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F162442\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F162418\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F162435\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F162419\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9662304\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9662305\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162394\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F162379\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50640550\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F162396\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F162395\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162450\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162386\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162399\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162383\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F162437\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162388\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9662223\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F162390\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F759349\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20306043\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F162392\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162382\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F162398\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F162402\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F162403\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8592|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dolasetron-patient-drug-information\" class=\"drug drug_patient\">Dolasetron: Patient drug information</a></li><li><a href=\"topic.htm?path=dolasetron-pediatric-drug-information\" class=\"drug drug_pediatric\">Dolasetron: Pediatric drug information</a></li></ul></div></div>","javascript":null}